RESEARCH MONOGRAPH · KDC-MN-257

Pindolol

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

69/100

Beta-blocker plus 5-HT1A partial agonist; the dual profile makes it a useful augmentation probe

Pindolol is the beta-blocker that quietly does two things, and the second one is what makes it interesting as a research compound. Beyond the non-selective beta-adrenergic antagonism (with significant intrinsic sympathomimetic activity, unlike propranolol), pindolol is a partial agonist at 5-HT1A receptors, particularly the presynaptic autoreceptors on raphe neurons.

That second mechanism is the whole reason it became the subject of an interesting line of clinical research in the 1990s and 2000s on SSRI augmentation. The hypothesis was that blocking the negative-feedback autoreceptor at the start of SSRI treatment should accelerate the typical 3-to-6 week delay in antidepressant onset. The Artigas group in Barcelona pushed this hard, and the early Blier and Bordet trials suggested real effects on response speed in MDD. Subsequent larger replications were mixed, and the modern view is that the effect is real but smaller and more dose-sensitive than the initial enthusiasm suggested.

What we like for research use is exactly this dual profile. If you want a tool compound that probes 5-HT1A autoreceptor function in the context of cardiovascular variables you can control independently, pindolol is one of the better-characterized options. The 5-HT1A affinity is in the low nanomolar range, the beta-adrenergic affinity is high, and the partial agonist character at both targets means you get more nuanced dose-response than pure antagonists give you.

The catch is dose-dependent receptor selectivity. At lower exposures pindolol behaves more like a 5-HT1A ligand; at higher exposures the beta-blockade dominates. For clean pharmacology you need to design your dosing carefully and ideally pair with control compounds (atenolol for peripheral beta, WAY-100635 for 5-HT1A) to disentangle which mechanism is doing what.

Sourcing is decent. Off-patent, available globally, the racemic mixture is the standard but the S-(-)-enantiomer carries most of the beta-blocking activity and a different 5-HT1A profile than R-(+). Single-enantiomer material is available for SAR work and worth the extra cost.

The augmentation literature gives pindolol modest clinical reliability for accelerating SSRI response in some subpopulations. As a research tool it's more useful for what it tells you about 5-HT1A autoreceptor pharmacology than for what it does to symptoms. Slept on outside of the serotonergic-pharmacology niche.

Evidence: 70
Mechanism: 78
Reliability: 60
Safety: 78
Sourcing: 75
Value: 70
Signal: 60
Staying power: 60

Plain-language summary Intrigue 48 / 100

Pindolol is an old beta-blocker, FDA-approved in 1982, that lowers blood pressure by quieting the heart. What makes it interesting outside cardiology is a side activity: it binds tightly to a serotonin receptor (5-HT1A) that normally throttles serotonin release. By turning off that throttle alongside an SSRI antidepressant, pindolol was hypothesized to make the SSRI kick in faster (days rather than weeks). Trials produced mixed results, with some studies showing accelerated response in depression and others showing nothing. It is still used occasionally in psychiatry as an SSRI booster, but never became standard practice. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Non-selective beta-adrenergic antagonist with 5-HT1A partial agonism

A non-selective beta-blocker with intrinsic 5-HT1A partial agonism; investigated as an SSRI augmenting agent.

Abstract

Pindolol (1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 13523-86-9; molecular formula C14H20N2O2; molecular weight 248.32) is a non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonism) and 5-HT1A partial agonism, approved by the FDA in 1982. The compound's distinguishing pharmacological feature in psychiatric research is high-affinity 5-HT1A binding (Ki approximately 50 nM) with partial agonist activity at presynaptic autoreceptors; concurrent administration with an SSRI desensitizes the autoreceptor more rapidly than the SSRI alone, hypothetically accelerating the antidepressant response. Multiple placebo-controlled trials in the 1990s and 2000s reported faster onset (1 to 2 weeks shorter latency) but inconsistent overall efficacy improvement. Plasma half-life is 3 to 4 hours; metabolism is hepatic. Approved indications in cardiology include hypertension and angina; the SSRI augmentation use remains off-label. Used as the canonical 5-HT1A binding beta-blocker in mechanism studies.

Mechanism of action

Non-selective beta-adrenergic antagonism plus 5-HT1A partial agonism (Ki approximately 50 nM). Used to accelerate SSRI antidepressant onset by autoreceptor desensitization.

Reported research dose ranges

Clinical 5 to 30 mg in the published literature; SSRI augmentation 2.5 to 7.5 mg in the published literature. Rodent studies 1 to 10 mg/kg.

References

Artigas F, et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996.
Perez V, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997.
Tome MB, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-257

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Pindolol

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs